Dirtan Tablet 80 mg (Valsartan)
Valsartan 80mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.
MFDS item code 201503909 · Approved 2015.06.16
This product's status changed to Expired on 2025.06.16. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension and heart failure; reduction of the risk of death after myocardial infarction
This medicine is used for essential hypertension as well as for the reduction of mortality risk after myocardial infarction and to treat heart failure. It is particularly effective for heart failure patients who are intolerant to ACE inhibitors. After a myocardial infarction, it helps reduce the risk of death in stable patients with left ventricular dysfunction and reduced systolic function. Therefore, it plays an important role in managing hypertension and improving cardiac function, effectively enhancing the cardiovascular health of patients.
1. Essential hypertension Take with water during or between meals. It is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended oral dose is valsartan 80 mg once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be added. If further blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg daily. 2) Older adults (aged 75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is required. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients undergoing dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high-dose diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg twice daily. Over the following several weeks, increase the dose according to the patient's tolerability to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if hypotension or renal failure occurs. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is required for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients undergoing dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of increasing the dose outweigh the risks. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension 6) Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Pediatric patients: Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication may cause severe harm to the fetus, especially when taken during the second and third trimesters of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Individuals with an allergy to this medication, women who are pregnant or may become pregnant, and breastfeeding women should not take this medication. Patients with severely impaired liver function or certain liver diseases, as well as those with severe kidney dysfunction, should refrain from using this medication. Patients with a history of angioedema or those experiencing angioedema symptoms while taking ACE inhibitors or angiotensin II receptor antagonists should avoid this medication. Elderly individuals, patients with high potassium levels, and those with mildly impaired liver function should use this medication with caution, and dosage adjustments may be necessary. This medication may cause a sudden drop in blood pressure upon initial use, which can lead to dizziness or fainting, especially in patients undergoing dialysis or taking diuretics; thus, it should be started at a lower dose gradually. During treatment with this medication, regular monitoring of blood pressure, kidney function, and electrolyte levels is essential to ensure no abnormalities occur. Taking this medication with potassium-sparing diuretics or potassium supplements may dangerously increase blood potassium levels, so caution is advised. Furthermore, taking it in conjunction with non-steroidal anti-inflammatory drugs (NSAIDs) may reduce its antihypertensive effects and impact kidney function, so caution is warranted. This medication may cause dizziness while driving or operating machinery, so attention is needed. Overdose may result in hypotension, reduced consciousness, shock, etc., thus requiring immediate appropriate treatment in a hospital. The safety and efficacy of this medication have not been fully established in children and adolescents, therefore its use is not recommended. Lastly, this medication should be kept out of reach of children, and it should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent air or moisture ingress. Additionally, it should be kept in a cool place below 30 degrees Celsius to maintain its efficacy.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Valsartan 80mg
Tablet · Prescription medication
Celltrion Pharmaceutical Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.